GSTC (GlobeStar Therapeutics) Tax Provision : $0.00 Mil (TTM As of Jun. 2024)

View and export this data going back to 2011. Start your Free Trial

What is GlobeStar Therapeutics Tax Provision?

GlobeStar Therapeutics's tax provision for the three months ended in Jun. 2024 was $0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Jun. 2024 was $0.00 Mil.

GlobeStar Therapeutics Tax Provision Historical Data

The historical data trend for GlobeStar Therapeutics's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlobeStar Therapeutics Tax Provision Chart

GlobeStar Therapeutics Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Tax Provision

Get a 7-Day Free Trial

GlobeStar Therapeutics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Tax Provision	Get a 7-Day Free Trial															-	-	-	-	-

GlobeStar Therapeutics Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

GlobeStar Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlobeStar Therapeutics Corp (OTCPK:GSTC) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

N/A

Address

719 Jadewin Avenue, Richland, WA, USA, 99352

Website

https://www.globestarthera.com

GlobeStar Therapeutics Corp is a clinical-stage pharmaceutical company introducing a patented formulation of previously approved drugs for the treatment of Multiple Sclerosis. The company is focused on developing therapies for people with serious and life-threatening rare disorders.

Executives

James C Katzaroff	director, officer: CEO	719 JADWIN AVE., RICHLAND WA 99352
William J Farley	director	468 ALBERN AVE, OCEANSIDE NY 11572
Robert Chicoski	officer: CFO	145 NEWTON ROAD, HAVERHILL MA 01830
Alex K Blankenship	director, officer: CEO, Pres., Secr., Treas.	14001 WALDEN RD., SUITE 600, MONTGOMERY TX 77356
Brent Atwood	10 percent owner	5000 RIVERSIDE DR STE100E, IRVING TX 75039
Bruce C Badeau	director	770 S. POST OAK LN., STE. 360, HOUSTON TX 77056
Robert W Fryer	director	1520 ENCLAVE, # 1208, HOUSTON TX 77077
Robert Federowicz	director, officer: Interim CEO & Chairman	495 GRAND BLVD., SUITE 206, MIRAMAR BEACH FL 32550